OLMA vs. NTLA, BGM, RCUS, VIR, RCKT, COLL, XNCR, REPL, PAHC, and DAWN
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT), Collegium Pharmaceutical (COLL), Xencor (XNCR), Replimune Group (REPL), Phibro Animal Health (PAHC), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs.
Olema Pharmaceuticals (NASDAQ:OLMA) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Intellia Therapeutics had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 34 mentions for Intellia Therapeutics and 21 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.63 beat Intellia Therapeutics' score of 0.25 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.
Olema Pharmaceuticals presently has a consensus target price of $27.50, suggesting a potential upside of 564.25%. Intellia Therapeutics has a consensus target price of $37.56, suggesting a potential upside of 351.93%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Intellia Therapeutics.
91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 19.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Olema Pharmaceuticals has higher earnings, but lower revenue than Intellia Therapeutics. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Intellia Therapeutics received 408 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 70.00% of users gave Olema Pharmaceuticals an outperform vote while only 68.90% of users gave Intellia Therapeutics an outperform vote.
Intellia Therapeutics' return on equity of -49.34% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.
Summary
Olema Pharmaceuticals beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 3/27/2025 by MarketBeat.com Staff
